QUOTE AND NEWS
DailyFinance  Mar 26  Comment 
SUNRISE, FL -- (Marketwired) -- 03/26/14 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will enroll patients in a new study for...
DailyFinance  Mar 21  Comment 
SUNRISE, FL -- (Marketwired) -- 03/21/14 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 31st American...
DailyFinance  Mar 17  Comment 
SUNRISE, FL -- (Marketwired) -- 03/17/14 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of...
DailyFinance  Jan 29  Comment 
SUNRISE, FL -- (Marketwired) -- 01/29/14 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that its first successful adipose derived stem...
DailyFinance  Dec 31  Comment 
SUNRISE, FL -- (Marketwired) -- 12/31/13 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the Vail Symposium...
DailyFinance  Dec 19  Comment 
SUNRISE, FL -- (Marketwired) -- 12/19/13 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, reports that Mike Tomas, president and CEO, underwent...
DailyFinance  Dec 17  Comment 
SUNRISE, FL -- (Marketwired) -- 12/17/13 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will enroll patients in a study for dry...
DailyFinance  Dec 2  Comment 
SUNRISE, FL -- (Marketwired) -- 12/02/13 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it has entered into an agreement with...
Globe Newswire  Jun 26  Comment 
SUNRISE, Fla., June 26, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that the company has launched a new brand image and redesigned website including a new company logo and tagline aimed at increasing brand awareness and
Globe Newswire  Jun 25  Comment 
SUNRISE, Fla., June 25, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that Kristin Comella, the company's Chief Science Officer presented at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in




 

Bioheart (OTC: BHRT; Twitter: $BHRT) seeks to be the "go to technology partner for heart failure specialists and their patients".

The company's flagship product MyoCell is an adult muscle stem cell composition, also known as immature myoblasts, derived and processed from patient's own thigh muscle. These cells are delivered to a patient's heart via the MyoCath needle tipped catheter or a similar device which is inserted through the patient's groin and is directed to the inside myocellof the heart where the injections are made.

MyoCell has been in clinical trials for treating advanced heart failure patients since early 2001. A 2nd generation composition MyoCell SDF-1 received FDA approval for clinical trials. This composition is made up of genetically modified cells that over express the stromal derived factor 1 protein that has been shown to improve blood vessel formation and muscle development.

Bioheart. has also initiated clinical evaluation of methods of treating heart ischemia, acute myocardial infarctions and lower limb ischemia utilizing adipose (fat) derived cells. Bioheart is focused on heart failure and has a building pipeline of product developments to assist care providers in treating and caring for these patients.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki